Results 181 to 190 of about 54,917 (299)

Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose‐ and comparator‐specific efficacy and safety. Methods PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched through 30 June 2026 for randomized controlled trials.
Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram, Kaeshaelya Thiruchelvam   +3 more
wiley   +1 more source

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes.
Tomoaki Morioka, Daichi Miyaoka, Susumu Nakatani, Yoshinori Kakutani, Shoko Miyamoto, Yu Nagakura, Miho Uematsu, Takehiro Hirano, Hidekatsu Yae, Mako Yamamoto, Noriaki Sato, Kosuke Fujimoto, Masanori Emoto, Seiya Imoto, Satoshi Uematsu   +14 more
wiley   +1 more source

SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications. [PDF]

Mol Biomed
Zheng XT, Xie HY, Wang XH, Zhao Y, Yang JY, Liu YX, Yuan XL, Tang HF, Jiang ZS, Hu HJ.   +9 more
europepmc   +1 more source

Response to “Methodological Considerations in Interpreting Renal [18F]FDG‐PET After Short‐Term Dapagliflozin Treatment”

Diabetes, Obesity and Metabolism, EarlyView.
Shawn Gugliandolo, Patricia Iozzo, Lucia Leccisotti, Francesca Cinti   +3 more
wiley   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists. [PDF]

Saudi J Anaesth
Majeed A, Amir RR, Dar SR, Mahmood A.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang, Ying Lu, Xinyao Jian, Haoyuan Wang, Jacquelyn Hatch‐Stein, Ronen Stein, Jennifer Panganiban, Yong Chen   +7 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

SGLT1 inhibition in cystic fibrosis: From preclinical evidence to clinical potential. [PDF]

Mol Ther Adv
Liang X, Liu Y, Jia S, Zhang K, Xu J.
europepmc   +1 more source

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

Journal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür, Emin Koyun, Gülşen Genç Tapar, Kayıhan Karaman, Metin Karayakali, Ataç Çelik, Uğur Kulu, Yasin Taşkin   +7 more
wiley   +1 more source